Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular mucins: targets for immunotherapy

V Apostolopoulos1, I F McKenzie

  • 1Austin Research Institute, Heidelberg, Victoria, Australia.

Critical Reviews in Immunology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fucosyl transferase (H) transgenic heart transplants to Gal-/- mice.

Transplantation·2000
Same author

Human monocytes bind to ligands on porcine endothelium containing the gal alpha (1,3)-Gal antigen.

Transplantation proceedings·2000
Same author

Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice.

Vaccine·2000
Same author

Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway.

European journal of immunology·2000
Same author

A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo.

European journal of immunology·2000
Same author

The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan.

Vaccine·2000
Same journal

Leveraging Type I Interferons: Exploring Pathogenesis and Therapeutic Strategies in Autoimmune Diseases.

Critical reviews in immunology·2026
Same journal

SLC2A1-Dependent Ketone Metabolism Regulates Tumor Progression and Immunotherapy Efficacy in Lung Adenocarcinoma.

Critical reviews in immunology·2026
Same journal

Knockdown of IGF2BP2 Inhibits THBS1 in Regulating the Progression of Oral Squamous Cell Carcinoma: An Integrative Analysis.

Critical reviews in immunology·2026
Same journal

Plasmodium Phosphatidylinositol 4-Kinase Beta (PI4Kβ): An Emerging Target at the Interface of Parasite Biology and Host Immunity.

Critical reviews in immunology·2026
Same journal

Fusion Gene EPHB4-MET Driven by HOXA9 and Exerted Oncogenic Activity in Non-Small Cell Lung Cancer.

Critical reviews in immunology·2026
Same journal

Secreted Phosphoprotein 1 Represents a Therapeutic Target that Promotes the Progression of Ovarian Cancer by Driving M2 Macrophage Infiltration.

Critical reviews in immunology·2026
See all related articles

Mucin 1 (MUC1) cancer vaccines target unique MUC1 epitopes on cancer cells. These epitopes, including the APDTR peptide, stimulate immune responses for potential cancer immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Mucins, particularly Mucin 1 (MUC1), are overexpressed and aberrantly glycosylated in various adenocarcinomas, presenting unique epitopes absent in normal tissues.
  • These MUC1 alterations include a 10-fold increase in expression, ubiquitous presence, and the appearance of novel carbohydrate and peptide neo-epitopes.

Purpose of the Study:

  • To explore the potential of MUC1 as a target for cancer immunotherapy, specifically in the development of vaccines for MUC1-expressing cancers.
  • To investigate the immunogenicity of MUC1 epitopes and their role in stimulating anti-cancer immune responses.

Main Methods:

  • Cloning of mucin cDNAs, particularly MUC1, to identify immunogenic regions.
  • Characterization of peptide epitopes, such as APDTR, within the MUC1 variable number of tandem repeats (VNTR).

Related Experiment Videos

  • In vitro stimulation of cytotoxic T lymphocytes (CTLs) from cancer patients' lymph nodes against MUC1 peptides.

    • Main Results:

    • Identification of a highly immunogenic peptide within the MUC1 VNTR, capable of eliciting strong antibody production in mice.
    • Demonstration that human breast cancer patients possess CTL precursors reactive to MUC1 peptides, notably APDTR.
    • Observation that these tumor-associated CTLs are non-MHC restricted.

    Conclusions:

    • MUC1-derived peptides and neo-carbohydrate epitopes are viable targets for cancer immunotherapy.
    • Development of MUC1-based cancer vaccines using synthetic carbohydrates or peptides conjugated with adjuvants is underway.
    • Clinical trials are ongoing to assess the immunogenicity and efficacy of these novel cancer vaccines.